Intracellular delivery of liposome-encapsulated prolidase in cultured fibroblasts from prolidase-deficient patients
- PMID: 15653144
- DOI: 10.1016/j.jconrel.2004.09.013
Intracellular delivery of liposome-encapsulated prolidase in cultured fibroblasts from prolidase-deficient patients
Abstract
Prolidase is a cytosolic exopeptidase whose deficiency causes the development of a rare autosomal recessive disorder known as Prolidase Deficiency (PD). The main manifestations of PD are intractable ulcerations of the skin, recurrent infections and mental retardation. At this time only a hazardous and expensive chronic therapy based on blood transfusions is the suggested treatment for PD. The aim of this work was to investigate the capability of utilizing liposomes as enzyme carriers: these vesicular systems have been recently evaluated as protein carriers for their potential in terms of "in vivo" localization, drug release and for protein stabilization in biological fluids. Liposomes were prepared, with a 1:1 PC:Col molar ratio with or without DSPE-PEG, by a thin-film hydration. Ex-vivo experiments were performed, incubating prolidase loaded liposomes with cultured fibroblasts from PD patients and from controls, to determine the amount of active enzyme delivered to cells. Evaluation of liposomes toxicity on cultured skin fibroblasts showed that liposomes did not interfere with cellular growth. Results showed that all the active prolidase encapsulated in the liposomes was completely vehiculated inside fibroblasts after 6 days incubation. SEM analysis suggests that prolidase is vehiculated inside the cell through liposome endocytosis.
Similar articles
-
Biodegradable microspheres for prolidase delivery to human cultured fibroblasts.J Pharm Pharmacol. 2004 May;56(5):597-603. doi: 10.1211/0022357023349. J Pharm Pharmacol. 2004. PMID: 15142336
-
Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase.Int J Pharm. 2008 Jun 24;358(1-2):230-7. doi: 10.1016/j.ijpharm.2008.03.012. Epub 2008 Mar 21. Int J Pharm. 2008. PMID: 18455892
-
Ex vivo evaluation of prolidase loaded chitosan nanoparticles for the enzyme replacement therapy.Eur J Pharm Biopharm. 2008 Sep;70(1):58-65. doi: 10.1016/j.ejpb.2008.04.014. Epub 2008 Apr 27. Eur J Pharm Biopharm. 2008. PMID: 18547793
-
The role of emerging techniques in the investigation of prolidase deficiency: from diagnosis to the development of a possible therapeutical approach.J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):1-8. doi: 10.1016/j.jchromb.2005.12.049. Epub 2006 Jan 24. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16434239 Review.
-
Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations.Amino Acids. 2008 Nov;35(4):739-52. doi: 10.1007/s00726-008-0055-4. Epub 2008 Mar 14. Amino Acids. 2008. PMID: 18340504 Review.
Cited by
-
Clinical Genetics of Prolidase Deficiency: An Updated Review.Biology (Basel). 2020 May 21;9(5):108. doi: 10.3390/biology9050108. Biology (Basel). 2020. PMID: 32455636 Free PMC article. Review.
-
PROLIDASE: A Review from Discovery to its Role in Health and Disease.Front Mol Biosci. 2021 Aug 31;8:723003. doi: 10.3389/fmolb.2021.723003. eCollection 2021. Front Mol Biosci. 2021. PMID: 34532344 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources